HLVX
Price:
$2.09
Market Cap:
$104.76M
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.
Industry
Biotechnology
IPO Date
2022-04-29
Stock Exchange
NASDAQ
Ticker
HLVX
According to HilleVax, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 26.39. This represents a change of 37.46% compared to the average of 19.20 of the last 4 quarters.
The mean historical Current Ratio of HilleVax, Inc. over the last ten years is 7.47. The current 26.39 Current Ratio has changed 35.22% with respect to the historical average. Over the past ten years (40 quarters), HLVX's Current Ratio was at its highest in in the September 2022 quarter at 34.77. The Current Ratio was at its lowest in in the December 2019 quarter at 0.
Average
7.47
Median
5.58
Minimum
0.15
Maximum
22.28
Discovering the peaks and valleys of HilleVax, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 3.97%
Maximum Annual Current Ratio = 22.28
Minimum Annual Increase = -61.67%
Minimum Annual Current Ratio = 0.15
| Year | Current Ratio | Change |
|---|---|---|
| 2024 | 10.84 | 2.10% |
| 2023 | 10.62 | -52.34% |
| 2022 | 22.28 | 3.97% |
| 2021 | 0.55 | 255.41% |
| 2020 | 0.15 | -61.67% |
The current Current Ratio of HilleVax, Inc. (HLVX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
14.58
5-year avg
8.89
10-year avg
7.47
HilleVax, Inc.’s Current Ratio is greater than Jounce Therapeutics, Inc. (8.37), greater than RVL Pharmaceuticals plc (2.89), greater than Tourmaline Bio, Inc. (24.68), less than Cyteir Therapeutics, Inc. (28.07), greater than Aadi Bioscience, Inc. (20.41), greater than Opiant Pharmaceuticals, Inc. (10.10), greater than Insight Molecular Diagnostics Inc. (4.04), greater than Decibel Therapeutics, Inc. (4.81), greater than Miromatrix Medical Inc. (5.52), greater than Berkeley Lights, Inc. (3.89),
| Company | Current Ratio | Market cap |
|---|---|---|
| 8.37 | $98.95M | |
| 2.89 | $3.14M | |
| 24.68 | $1.23B | |
| 28.07 | $108.71M | |
| 20.41 | $94.89M | |
| 10.10 | $108.80M | |
| 4.04 | $159.95M | |
| 4.81 | $123.37M | |
| 5.52 | $92.95M | |
| 3.89 | $86.61M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like HilleVax, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like HilleVax, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Current Ratio?
How can you use the Current Ratio?
What is HilleVax, Inc.'s Current Ratio?
How is the Current Ratio calculated for HilleVax, Inc. (HLVX)?
What is the highest Current Ratio for HilleVax, Inc. (HLVX)?
What is the 3-year average Current Ratio for HilleVax, Inc. (HLVX)?
What is the 5-year average Current Ratio for HilleVax, Inc. (HLVX)?
How does the current Current Ratio for HilleVax, Inc. (HLVX) compare to its historical average?